Overview


According to FutureWise analysis the market for real-world evidence solutions in 2023 is US$ 1.73 billion, and is expected to reach US$ 5.45 billion by 2031 at a CAGR of 15.40%.

Randomised Controlled Trial are used to obtain results over a small patient set in a highly contained environment in a short time and across clinical trial centres that are dispersed. The life science companies have cited the potential of real-world data which is why they are emphasizing on evaluating the cost efficiency of drugs in real time and understanding their effect on the quality of healthcare. To fulfil the rising needs of the healthcare industry, there is a surging insistence for real-world proofs that rely on patient data registered by the administrators and practitioners during daily course. The data is collected from different sources and are used for making decisions, developing drugs and devices, reducing costs, improvements in the coordination of care and post-market monitoring.

  • Anthem, Inc.
  • Clinigen Group plc
  • Cognizant
  • IBM Corporation
  • ICON plc
  • IQVIA
  • Optum,Inc.
  • Oracle Corporation
  • PAREXEL International Corporation
  • PerkinElmer Inc.
  • Pharmaceutical Product Development LLC.
  • SAS Institute Inc.
  • Syneos Health
  • Symphony Innovation LLC
  • Medpace Holding Corportaion

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Component

  • Data Sets
    • Clinical Settings Data
    • Claims Data
    • Pharmacy Data
    • Patient-Powered Data
  • Services

By Therapeutic area

  • Oncology
  • Cardiovascular Disease
  • Neurology
  • Immunology
  • Others

By Application

  • Market Access & Reimbursement/Coverage Decisions

  • Drug Development & Approvals   

    • Oncology
    • Neurology
    • Immunology
    • Cardiovascular Diseases
    • Other Therapeutic Areas
  • Post Market Surveillance
  • Medical Device Development & Approvals
  • Other Applications

By End User

  • Pharmaceutical and Biopharmaceutical Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

The market is divided into component, Therapeutic area, end user and region. The component segment is fragmented into data sets and consulting. The data sets segment is fragmented into disparate data sets and integrated data sets. The data sets segment is predicted to hold the largest real-world evidence solutions market share owing to an increase in the amount of medical data that is generated in hospitals, rising dependence of studies based on outcomes on the basis of real world data, increased insistence for regulatory providers and bodies and payer information pertaining to drug safety. The application segment is categorised into oncology, CVD, neurology, infection, drug development and regulatory. The drug development and approvals segment dominated the market, and this can be credited to surging demand of RWE and RWD to boost the drug development and discovery, rising investments made by the biopharma companies in research and development activities. The end user segment is fragmented into pharmaceutical and biopharma companies, healthcare payers, healthcare providers and other end users. The pharmaceutical and biopharma companies lead the market, and this can be credited to the rising importance of studies pertaining to RWE in drug approvals and development, increased emphasis in avoiding expensive drug recalls.

The North America region is predicted to dominate the market and this can be credited to the availability of data sets that are real-world, rising emphasis on care based on values, increased expenditure on research and development by biopharma companies, increased focus on early device and drug approvals and development and a strong presence of key market players in the region. Furthermore, strict rules and regulation for approving drugs and bolstering policies of the government.

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key market trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Global Real-world Evidence Solutions Market By Component, By Therapeutic Area, By Application, By End User and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Real-World Evidence Solutions Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Real-World Evidence Solutions Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Real-World Evidence Solutions Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Real-World Evidence Solutions Market, By Component Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Data Sets
         1.1. Clinical Settings Data
         1.2. Claims Data
         1.3. Pharmacy Data
         1.4. Patient-Powered Data
        2. Services

  • 8.   Real-World Evidence Solutions Market, By Therapeutic Area Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oncology
        2. Cardiovascular Disease
        3. Neurology
        4. Immunology
        5. Others

  • 9.  Real-World Evidence Solutions Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Market Access & Reimbursement/Coverage Decisions
        2. Drug Development & Approvals
         2.1. Oncology
         2.2. Neurology
         2.3. Immunology
         2.4. Cardiovascular Diseases
         2.5. Other Therapeutic Areas
        3. Post Market Surveillance
        4. Medical Device Development & Approvals
        5. Other Applications

  • 10.   Real-World Evidence Solutions Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pharmaceutical and Biopharmaceutical Companies
        2. Healthcare Payers
        3. Healthcare Providers
        4. Other End Users

  • 11.   North America Real-World Evidence Solutions Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Real-World Evidence Solutions Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Real-World Evidence Solutions Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Real-World Evidence Solutions Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Anthem, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Clinigen Group plc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Cognizant
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. IBM Corporation
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. ICON plc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. IQVIA
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Optum Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Oracle Corporation
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. PAREXEL International Corporation
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. PerkinElmer Inc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Pharmaceutical Product Development LLC
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. SAS Institute Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Syneos Health
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Symphony Innovation LLC
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Medpace Holding Corportaion
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients